- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.05. | Elicera Therapeutics AB: Elicera Therapeutics enters a Material Transfer Agreement with University Hospital Tübingen for testing of the company's oncolytic virus candidates, ELC-100 and ELC-201 | 126 | GlobeNewswire (Europe) | Gothenburg, May 28, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology... ► Artikel lesen | |
| 22.05. | Elicera Therapeutics AB: Elicera reports: Active lymphoma eliminated in two out of three patients in the first cohort of the CARMA study with iTANK-armed CAR T-cell therapy | 126 | GlobeNewswire (Europe) | Gothenburg, May 22, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 15.05. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 31 March 2025 | 137 | GlobeNewswire (Europe) | First quarter (January-March 2025)
Operating loss amounted to SEK -8,069,404 (-5,433,422).
Loss for the period amounted to SEK -8,013,462 (-5,369,677).
Cash flow from operating activities totalled... ► Artikel lesen | |
| 14.04. | ELICERA THERAPEUTICS: Green light to continue Elicera's CARMA-trial in B-cell lymphoma | 2 | Cision News | ||
| 10.04. | Elicera Therapeutics AB: Elicera Therapeutics continues the Phase I/IIa CARMA study with its CAR T-cell therapy as planned following the safety committee's assessment of cohort 1 | 270 | GlobeNewswire (Europe) | Gothenburg, April 10, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 20.03. | Elicera Therapeutics resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO2 | 3 | Cision News | ||
| 13.03. | Warrants of series TO2 in Elicera Therapeutics AB were subscribed to approximately 96.3 percent and the company resolves on a directed issue to underwriters | 1 | Cision News | ||
| 07.03. | The last day of trading with the warrants of series TO2 in Elicera Therapeutics is today, March 7, 2025 | 2 | Cision News | ||
| 03.03. | ELICERA THERAPEUTICS: Elicera's CEO: "TO2 is a highly attractive opportunity to increase ownership in Elicera" | 2 | Cision News | ||
| 28.02. | Correction: Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics | 2 | Cision News | ||
| 28.02. | Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics | 1 | Cision News | ||
| 26.02. | Elicera Therapeutics - Positioned to deliver in cell and gene therapies | 356 | Edison Investment Research | Elicera Therapeutics is a cell and gene therapy company utilising its iTANK platform to develop immunotherapies for solid and bloodborne tumours. Its pipeline comprises two CAR-T therapies and two oncolytic... ► Artikel lesen | |
| 25.02. | Elicera Therapeutics has secured 100 percent of the warrants of series TO2 corresponding to approximately SEK 22.0 million | 1 | Cision News | ||
| 25.02. | The exercise price for the warrants of series TO2 in Elicera Therapeutics has been determined to SEK 1.85 | 2 | Cision News | ||
| 03.02. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Year-end Report 1 January - 31 December 2024 | 146 | GlobeNewswire (Europe) | Fourth quarter (October-December 2024)
Operating profit/loss amounted to SEK -2,911,958 (-5,212,694).
Loss for the period amounted to SEK -2,603,242 (-4,749,222).
Cash flow from operating activities... ► Artikel lesen | |
| 28.11.24 | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 30 September 2024 | 106 | GlobeNewswire (Europe) | Third quarter (July-September 2024)
Operating profit/loss amounted to SEK -2,697,267 (-5,149,440).
Loss for the period amounted to SEK -2,514,629 (-5,046,574).
Cash flow from operating activities... ► Artikel lesen | |
| 29.08.24 | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 30 June 2024 | 102 | GlobeNewswire (Europe) | Second quarter (April-June 2024)
Operating profit/loss amounted to SEK -5,841,409 (-4 466 286).
Loss for the period amounted to SEK -5,622,779 (-4,335,852).
Cash flow from operating activities... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,318 | -0,60 % | Ihre wichtigsten Termine: Porsche, Thyssenkrupp Nucera, Eon, Evotec, Brenntag, Sixt & Tui legen Zahlen vor | © Foto: PorscheGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:45 Uhr, Deutschland:... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 492,90 | +0,20 % | Dividendenbekanntmachungen (18.08.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABN AMRO BANK NV ADR US00080Q1058 0,6283 USD 0,5368 EUR APOLLO GLOBAL MANAGEMENT INC US03769M1062 0,51 USD 0,4356 EUR ARKO CORP US0412421085 0... ► Artikel lesen | |
| BRAIN BIOTECH | 2,060 | +0,49 % | EQS-News: BRAIN Biotech AG: Erfahrene Biotechnologie-Expertin neu im Aufsichtsrat der BRAIN Biotech AG | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Personalie
Erfahrene Biotechnologie-Expertin neu im Aufsichtsrat der BRAIN Biotech AG
23.07.2025 / 08:30 CET/CEST
Für den... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| CARDIOL THERAPEUTICS | 1,050 | +0,77 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
12.08.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,610 | +3,87 % | Burcon NutraScience Corporation: Burcon Announces Fiscal 2026 First Quarter Results | Vancouver, British Columbia--(Newsfile Corp. - August 13, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CSL | 150,56 | +0,15 % | CSL Limited: CSL announces rise in full year net profit | Major strategic initiatives, including demerger, to transform CSL
MELBOURNE, Aug. 19, 2025 /PRNewswire/ -- Global biotherapeutics leader CSL today announced a reported net profit after... ► Artikel lesen | |
| MANNKIND | 3,299 | +0,89 % | MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,430 | -1,22 % | Oxford Nanopore CFO acquires shares through employee share plan | ||
| OCULAR THERAPEUTIX | 10,645 | +1,00 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company | BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, announced the launch... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,061 | +1,68 % | Adaptimmune Therapeutics PLC: Adaptimmune Reports Q2 Financial Results and Provides Business Update | Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to... ► Artikel lesen | |
| CODEXIS | 2,600 | +0,93 % | Stifel maintains Buy rating on Codexis stock amid strong business outlook | ||
| TELO GENOMICS | 0,014 | -17,65 % | Telo Genomics Corp.: Telo Genomics to Present at the OTCQB Venture Virtual Investor Conference | Toronto, Ontario--(Newsfile Corp. - August 5, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human... ► Artikel lesen | |
| BIORA THERAPEUTICS | 0,001 | -100,00 % | NSE - BIORA THERAPEUTICS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| CORMEDIX | 11,400 | +0,88 % | CorMedix, Inc.: CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update | ? Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ? Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ., May 06, 2025 (GLOBE NEWSWIRE) -- CorMedix... ► Artikel lesen |
ELICERA THERAPEUTICS AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,504 Euro und damit -1,56 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.